Browse the evidence

Replacing processed animal meats with plant-based meat analogues (PBMAs) significantly reduces saturated fat and total energy intake while increasing dietary fiber, leading to more favorable Nutri-Score ratings in most categories.

Switching from processed animal meats (like sausages and bacon) to plant-based analogues generally lowers your saturated fat and calorie intake while boosting fiber. However, check the label: many analogues are high in salt and sugar, and few are fortified with B12 or Iron. Choose products with lower sodium and consider a B12 supplement if you rely heavily on these substitutes.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce clinically significant weight loss (15-21%) and improve comorbidities, but require long-term continuous use to maintain benefits.

GLP-1 medications like semaglutide and tirzepatide are highly effective for significant weight loss (15-21%) and improving health conditions like diabetes and heart disease. However, they are not cosmetic shortcuts. You must commit to long-term use, as stopping the medication usually leads to regaining the weight. Work with your doctor to manage side effects and adjust other medications as you lose weight.

GLP-1/GIP dual receptor agonists (e.g., tirzepatide) produce significantly greater weight loss than GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and non-GLP-1 agents (e.g., orlistat, phentermine/topiramate) in weight management trials.

If you are struggling with obesity, GLP-1/GIP dual agonists like tirzepatide are currently the most effective pharmacological option for weight loss, significantly outperforming older medications and even single-target GLP-1 agonists. This comes with the need for weekly injections (or oral alternatives) and careful dose escalation to manage side effects.

GLP-1 receptor agonists (semaglutide 2.4 mg weekly) and dual incretin agonists (tirzepatide) significantly reduce hepatic steatosis and improve or resolve steatohepatitis (MASH) in patients with MASLD, primarily through sustained weight loss and improved insulin sensitivity.

If you have fatty liver disease linked to metabolic issues, GLP-1 medications like semaglutide are currently the most effective pharmacological tool to reverse liver inflammation and fat. They work by targeting the root metabolic causes rather than just the liver itself. Consult a doctor to see if you qualify for these treatments, especially if lifestyle changes alone haven't resolved your liver health markers.

Intensive lifestyle interventions (dietary restriction and exercise) can induce type 2 diabetes remission, with remission rates strongly dose-dependent on the magnitude of weight loss, particularly when exceeding 15 kg.

To achieve type 2 diabetes remission, you must lose a significant amount of weight, ideally 15 kg or more, through a combination of calorie-restricted diet and regular exercise (at least 150 minutes/week). This is not just about weight loss; it requires a multidisciplinary support system including dietitians and psychological counseling to manage the mental burden of strict lifestyle changes. Shorter diabetes duration and higher BMI (27-45) predict better success.

Tirzepatide, a dual GLP-1/GIP receptor agonist, provides greater HbA1c reduction and weight loss compared to semaglutide 1 mg in patients with Type 2 Diabetes.

If you need significant weight loss and blood sugar control, ask your doctor about tirzepatide. It may work better than older GLP-1 drugs like semaglutide 1 mg, but it is more expensive.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce significant weight loss (10-21%) but also reduce lean body mass, necessitating resistance training to preserve muscle and performance in physically active individuals.

If you are using GLP-1 agonists like semaglutide or tirzepatide for weight loss, expect to lose both fat and some muscle. To protect your strength and athletic performance, you must incorporate resistance training into your routine. This combination helps offset the lean mass loss associated with these drugs. Do not rely on the medication alone; long-term maintenance requires continuous therapy and lifestyle adherence, as stopping treatment typically leads to weight regain.

Semaglutide (2.4 mg) is the most cost-effective and clinically effective pharmacological intervention for obesity treatment compared to other FDA-approved medications and lifestyle interventions.

For adults with obesity, Semaglutide (2.4 mg weekly) combined with diet and exercise is currently the most effective and economically favorable medication option available, outperforming older drugs like Orlistat in most healthcare settings.

Multidisciplinary therapy combining nutritional, physical, and behavioral interventions reduces body weight, fat mass, and cardiometabolic risk factors in adults with obesity.

To manage obesity effectively, you need a team approach that includes diet, exercise, and behavioral counseling, rather than just one of these. Aim for sessions 2-3 times a week, lasting at least 20 minutes, over a period of weeks to months. This combined approach helps reduce weight and fat while preserving muscle and improving metabolic health, which is crucial for long-term success.

Phenotype-guided treatment selection (matching drug mechanism to obesity subtype like 'hungry brain' or 'slow burn') results in significantly greater weight loss compared to standard care.

Ask your doctor about your obesity phenotype (e.g., 'hungry brain', 'slow burn'). Matching your medication to your specific metabolic or behavioral drivers can nearly double your weight loss success compared to standard treatment approaches.

Aerobic and resistance exercise reduce hepatic steatosis and improve insulin sensitivity in MASLD patients independently of significant body weight loss.

You do not need to lose weight to improve your liver health through exercise. Both aerobic exercise (45-60 minutes, 3-5 times a week) and resistance training (3 times a week for 8-12 weeks) can significantly reduce liver fat and improve insulin sensitivity, even if your body weight remains stable. Focus on consistency and metabolic health rather than just the number on the scale.

Tirzepatide (TZP) produces significantly greater weight loss than semaglutide (SEM) in patients with rheumatic and musculoskeletal diseases (RMDs), with TZP users losing 8.2% of body weight compared to 5.8% for SEM users at 12 months.

If you have a rheumatic condition and are using GLP-1 medications, Tirzepatide is associated with greater weight loss than Semaglutide. In this large study, Tirzepatide users lost 8.2% of their body weight at 12 months, compared to 5.8% for Semaglutide users. This benefit was observed even in patients with mobility limitations, suggesting that pharmacological intervention can overcome some barriers to weight loss in this population.

The effectiveness of protein supplementation on lean mass and strength is significantly higher in sarcopenic and frail older adults compared to overweight or obese older adults.

If you are an older adult who is frail, sarcopenic, or institutionalized, adding protein supplements to your resistance training is more likely to help you build lean mass and strength. If you are overweight or obese, you may not see these benefits, as your body's response to protein may be blunted by excess weight and lower activity levels.

Resistance exercise training (RET) volume is the primary driver of skeletal muscle hypertrophy, with higher weekly volumes yielding greater muscle growth up to a specific threshold.

To maximize muscle growth, focus on increasing your total training volume (sets x reps x weight) over time. You do not need to lift extremely heavy weights; moderate loads work just as well if you train close to failure. However, be aware that there is a limit to how much volume you can handle before gains stall or health suffers, so find your personal threshold.

Dietary protein intake supports but does not independently drive skeletal muscle hypertrophy; its primary role is to amplify the anabolic response to resistance exercise.

Eat enough protein (1.2-1.6 g/kg/day) to support your training, but do not expect it to build muscle on its own. The key to muscle growth is resistance exercise. Protein helps maximize the gains you get from your workouts.

Protein and essential amino acid (EAA) supplementation promotes measurable muscle hypertrophy (via ultrasound/MRI) only when daily intake is below 1.6 g/kg/day or per-meal leucine is below 2–3 g; benefits plateau once these thresholds are met.

If you already eat enough protein (around 1.6g per kg of body weight) or get enough leucine per meal (2-3g), adding more protein powder will not make your muscles grow bigger. Focus on hitting that baseline first; extra protein is wasted for hypertrophy purposes.

Creatine monohydrate (3–5 g/day) increases muscle thickness and cross-sectional area in resistance training interventions lasting 8–12 weeks or more, primarily by enabling higher training volume and quality rather than direct anabolic signaling.

Take 3-5g of creatine monohydrate daily. It won't magically build muscle overnight, but it will help you lift more volume over 8-12 weeks, which leads to actual muscle growth. Don't expect results in the first few weeks.

Female endurance athletes unintentionally underfuel with carbohydrates relative to training volume, creating a cumulative energy deficit, while simultaneously prioritizing protein intake to meet or exceed recommendations.

Female endurance athletes should prioritize carbohydrate intake on training days to match volume, as deficits increase significantly with higher loads. Do not neglect rest days; even low-intensity sessions require adequate fuel to prevent cumulative energy deficits. While protein intake is often correctly prioritized, ensure it does not displace necessary carbohydrates. Address psychological barriers like body image and time constraints by planning simple, accessible carbohydrate sources for all training days, not just hard sessions.

Structured, individualized nutritional interventions significantly improve sport-specific performance and increase energy availability in competitive female athletes compared to generic guidance.

If you are a competitive female athlete, generic advice is likely not enough. You need a personalized plan that targets at least 45 kcal per kg of fat-free mass daily. Focus on consuming 5-8g of carbs and 1.6-2.0g of protein per kg of body weight. Work with a professional to adjust this gradually to avoid psychological resistance, and monitor your energy availability regularly to ensure you are not in a deficit.

Individualized nutritional interventions significantly reduce the prevalence of Female Athlete Triad risk (LEAF-Q ≥ 8) in competitive female athletes.

If you are at risk for the Female Athlete Triad, screening alone is not enough. You need a structured nutritional plan that increases your energy availability to at least 45 kcal/kg of fat-free mass daily. This involves eating enough carbohydrates and protein to support your training load, monitored by a professional to ensure you are not in a deficit.

Individualized nutritional interventions significantly improve nutritional knowledge and reduce eating disorder risk behaviors (EDE-Q) in competitive female athletes.

To improve your nutritional knowledge and reduce risky eating behaviors, seek a structured educational program that is part of a larger individualized plan. This should include 6 sessions covering energy availability, carbohydrates, and recovery, tailored to your specific sport and needs.

Incretin receptor agonists (GLP-1RA, dual/triple agonists) and SGLT2 inhibitors reduce the risk of progression to type 2 diabetes and improve cardiovascular outcomes in patients with prediabetes, primarily through weight loss and reduction of visceral ectopic fat.

If you have prediabetes along with obesity, heart failure, or kidney disease, your doctor may consider newer medications like GLP-1 agonists (e.g., semaglutide) or SGLT2 inhibitors. These drugs help with weight loss and reduce cardiovascular risk. They are not yet first-line for all prediabetes patients due to cost and lack of formal indications, but they can be very effective for high-risk individuals.

Intensive lifestyle interventions (ILIs) targeting fat reduction (specifically visceral and body fat mass) significantly improve complete remission rates in overweight patients undergoing fertility-sparing treatment for endometrial cancer and intraepithelial neoplasia.

For overweight patients undergoing fertility-sparing treatment for endometrial precancer, intensive lifestyle changes focusing on fat loss (not just scale weight) significantly improve remission rates. This involves a caloric deficit, daily moderate aerobic exercise, and resistance training to protect muscle mass. Aim for a modest ~3% weight loss, as excessive loss may reduce efficacy by depleting muscle.

Lifestyle interventions during OMM treatment should shift focus from caloric deficit for weight loss to optimizing health, specifically by mitigating lean mass loss through high protein intake and resistance training.

While taking OMMs, prioritize consuming 1.5g of protein per kg of fat-free mass (or 80-120g daily) and engage in resistance training 2-3 times per week. This helps preserve muscle mass and strength, which can be lost during rapid weight loss, and supports overall physical function.